+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tissue Diagnostics Market - Forecasts from 2020 to 2025

  • ID: 5138746
  • Report
  • August 2020
  • Region: Global
  • 122 pages
  • Knowledge Sourcing Intelligence LLP

FEATURED COMPANIES

  • Abbott Laboratories
  • BD
  • Cancer Genetics, Inc.
  • Danaher
  • Medtronic
  • QIAGEN
The tissue diagnostics market is projected to grow at a CAGR of 7.16% to reach US$6.385 billion by 2025 from US$4.216 billion in 2019. Cancer is a major public health and economic issue and its burden is set to spiral. With over 18 million cases in 2018, 29 million cases by 2040 are expected due to the aging and growth of the population [Source: WHO]. Recognized as one of the global standards for cancer diagnosis, tissue diagnostics are integral to obtain the biological aspects of tumors. Moreover, with an increased incidence of cancer, the market for tissue diagnostics markets has witnessed a promising growth and is further estimated to grow during the forecast period. Moreover, there is a growing adoption rate pertaining to the automated tissue-based diagnostic systems due to its reported capabilities of swift diagnosis of tumors, by research institutions. For example. F. Hoffmann-La Roche Ltd partnered with West Clinic Cancer Center in 2019 with the objective to enhance patient care by employing Roche’s BenchMark ULTRA Automated Advanced Staining System that is used for immunohistochemical testing or in-situ hybridization enabling a faster diagnosis of tumors. Moreover, the revenue generation in the market is being propelled by the increasing focus of prime market players to develop advanced tissue-diagnostic based companion diagnostic tests. To this end, PD-L1 IHC 22C3 pharmDx assay, which is a qualitative immunohistochemical assay to identify non-small cell lung cancer, that was designed by Agilent in partnership with Merck received the FDA approval. Moreover, the anatomic pathology workflow is consistently evolving and are gradually being automated to a great extent. This transition from manual to automation is giving rise to novel solutions. Further, the rise in the standardization of processes in laboratories concomitantly the incorporation of automated molecular diagnostic technologies and incorporation of bioinformatics have led to a paradigm shift in pathology workflow and has enabled clinicians to prioritize critical cases, reduce the turnaround time and enhance patient outcomes. To this extent, in 2019, Alverno Laboratories in partnership with Royal Phillips integrated Philips' IntelliSite Pathology Solution in the clinical laboratories intending to improve laboratory efficiency, quality, and patient safety which exemplifies the benefits of adoption of digital pathology solution thereby contributing to the surge in the segment. In view of the above it is expected that during the forecast period, the technology segment of digital pathology will witness a meteoric growth. This is also in part due to the growing preference rate of whole-slide imaging (WSI) among the pathologies, which is one of the prime factors responsible for the growth of this subsegment. The rationale behind such a preference is that specific features of tumors can now be extracted by WSI thereafter enabling the quantification of each component of the features and support diagnosis of cancer simultaneously provide a clinical diagnosis of tumors. For example, Nikon Instruments Inc. launched a digital slide scanning system, OS-15-N, in partnership with OptraSCAN. In 2019. Again, during the same year, IntelliSite Pathology Solution by Philips was introduced across India by the HealthCare Global Enterprises Ltd.

In view of the application, the segment of Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide followed by breast cancer. Regarding both sexes combined, globally, lung cancer continues to be the most commonly diagnosed cancer (2.1 million, 12% of the total) and the leading cause of cancer death (1.8 million, 18%) because of its poor prognosis. Female breast cancer is the second most common cancer overall (2.1 million, 12%) but the fifth leading cause of cancer death (627,000, 7%) because of its relatively favorable prognosis. As such, it is the most prevalent cancer worldwide (6.9 million women living within 5 years of their breast cancer diagnosis. About one in twenty females will be diagnosed with breast cancer throughout their lifetime, although this number varies significantly by country. 2 Incidence rates are elevated in Australia/New Zealand, Europe, and North America, notably in Belgium (113 cases per 100,000 female population) and Luxembourg (109) in Europe, and Australia (94). In contrast, incidence rates in sub-Saharan African regions, particularly in Eastern (30 cases per 100,000 female population) and Middle Africa (28), as well as South-Central Asia (26), were considerably lower. Further, the lifetime risk of breast cancer among females in high-income countries can be up to three times that in low-income countries [ Source: WHO]. To this end, in 2020 Exact Sciences Corp. (NASDAQ: EXAS) announced that it would be presenting data to demonstrate the clinical value of the Oncotype DX Breast Recurrence Score® test and exemplify the research progress made by Exact Sciences' Mayo Clinic collaboration toward smarter solutions across the cancer continuum. Further, during the same year, OncBioMune Pharmaceuticals, Inc. (OTC PINK: OBMP) announced the successful completion of its purchase of all the assets of Avant Diagnostics, Inc. which provides personalized medicine data through its Theralink ®assays, initially for breast cancer, to assist the treating physician in a data-driven process for treatment decision support and to help enable predictive biomarker-based patient therapy selection. Besides development pertaining to breast cancers, during the same year, Veracyte, Inc. (Nasdaq: VCYT) which is a global genomic diagnostics company, announced that De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter ® Dx LymphMark ™ Assay, a novel, genomic lymphoma subtyping test.

Segmentation

By Product
  • Consumables
  • Antibodies
  • Kits
  • Probes
  • Reagents
  • Instruments
  • Slide Scanners
  • Slide Staining Systems
  • Tissue Microarrays
  • Tissue Processing Systems
  • Other Products
By Technology
  • Digital Pathology and Workflow Management
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Primary Special Staining
By Application
  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Gastric cancer
  • Lung cancer
  • Others
By End-Users
  • Contract Research Organizations (CROs)
  • Hospitals
  • Pharmaceutical Organizations
  • Research Laboratories
By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • The Middle East and Africa
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Others
This report will be delivered within 2 business days
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • BD
  • Cancer Genetics, Inc.
  • Danaher
  • Medtronic
  • QIAGEN
1. Introduction
1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Tissue Diagnostics Market, By Type
5.1. Introduction
5.2. Consumables
5.2.1. Antibodies
5.2.2. Kits
5.2.3. Probes
5.2.4. Reagents
5.3. Instruments
5.3.1. Slide Scanners
5.3.2. Slide Staining Systems
5.3.3. Tissue Microarrays
5.3.4. Tissue Processing Systems
5.3.5. Others

6. Tissue Diagnostics Market Analysis, By Technology
6.1. Introduction
6.2. Digital Pathology and Workflow Management
6.3. Immunohistochemistry (IHC)
6.4. In Situ Hybridization (ISH)
6.5. Primary Special Staining

7. Tissue Diagnostics Market Analysis, By Application
7.1. Introduction
7.2. Breast cancer
7.3. Cervical cancer
7.4. Colorectal cancer
7.5. Gastric cancer
7.6. Lung cancer
7.7. Others

8. Tissue Diagnostics Market Analysis, By End-User
8.1. Introduction
8.2. Contract Research Organizations (CROs)
8.3. Hospitals
8.4. Pharmaceutical Organizations
8.5. Research Laboratories

9. Tissue Diagnostics Market Analysis, by Geography
9.1. Introduction
9.2. North America
9.2.1. North America Tissue Diagnostics Market Analysis, By Product
9.2.2. North America Tissue Diagnostics Market Analysis, By Technology
9.2.3. North America Tissue Diagnostics Market Analysis, By Application
9.2.4. North America Tissue Diagnostics Market Analysis, By End-Users
9.2.5. By Country
9.2.5.1. USA
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. South America Tissue Diagnostics Market Analysis, By Product
9.3.2. South America Tissue Diagnostics Market Analysis, By Technology
9.3.3. South America Tissue Diagnostics Market Analysis, By Application
9.3.4. South America Tissue Diagnostics Market Analysis, By End-Users
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. Europe Tissue Diagnostics Market Analysis, By Product
9.4.2. Europe Tissue Diagnostics Market Analysis, By Technology
9.4.3. Europe Tissue Diagnostics Market Analysis, By Application
9.4.4. Europe Tissue Diagnostics Market Analysis, By End-Users
9.4.5. By Country
9.4.5.1. Germany
9.4.5.2. France
9.4.5.3. United Kingdom
9.4.5.4. Italy
1.1.1.1. Others
9.5. The Middle East and Africa
9.5.1. Middle East and Africa Tissue Diagnostics Market Analysis, By Product
9.5.2. Middle East and Africa Tissue Diagnostics Market Analysis, By Technology
9.5.3. Middle East and Africa Tissue Diagnostics Market Analysis, By Application
9.5.4. Middle East and Africa Tissue Diagnostics Market Analysis, By End-Users
9.5.5. By Country
9.5.5.1. Israel
9.5.5.2. Saudi Arabia
9.5.5.3. Others
9.6. Asia Pacific
9.6.1. Asia Pacific Tissue Diagnostics Market Analysis, By Product
9.6.2. Asia Pacific Tissue Diagnostics Market Analysis, By Technology
9.6.3. Asia Pacific Tissue Diagnostics Market Analysis, By Application
9.6.4. Asia Pacific Tissue Diagnostics Market Analysis, By End-Users
9.6.5. By Country
9.6.5.1. China
9.6.5.2. Japan
9.6.5.3. South Korea
9.6.5.4. India
9.6.5.5. Others

10. Competitive Environment and Analysis
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix

11. Company Profiles
11.1. Abbott Laboratories
11.2. Agilent Technologies, Inc.
11.3. AstraZeneca 2020
11.4. BD
11.5. BioGenex
11.6. Cancer Genetics, Inc.
11.7. Cardinal Health
11.8. Danaher
11.9. Exact Sciences Corporation
11.10. F. Hoffmann-La Roche Ltd
11.11. Genemed Biotechnologies, Inc.
11.12. Greiner Bio One International GmbH
11.13. McKesson Medical-Surgical Inc.
11.14. Medtronic
11.15. Merck KGaA
11.16. QIAGEN
11.17. SARSTEDT AG & Co. KG
11.18. Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca 2020
  • BD
  • BioGenex
  • Cancer Genetics, Inc.
  • Cardinal Health
  • Danaher
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Genemed Biotechnologies, Inc.
  • Greiner Bio One International GmbH
  • McKesson Medical-Surgical Inc.
  • Medtronic
  • Merck KGaA
  • QIAGEN
  • SARSTEDT AG & Co. KG
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll